L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized...

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Elevated Lipoprotein (a) [Lp(a)] is a significant, independent risk factor for cardiovascular disease.
• Current therapeutic strategies for lowering Lp(a) are limited.
• L-Carnitine has shown potential in reducing Lp(a) levels.

Purpose of the Study:

• To compare the efficacy of L-carnitine/simvastatin co-administration versus simvastatin monotherapy in reducing Lp(a) levels.
• To evaluate the impact of this combination therapy in patients with mixed hyperlipidemia and elevated Lp(a).

Main Methods:

• A randomized controlled trial involving 58 subjects with mixed hyperlipidemia and Lp(a) > 20 mg/dL.
• Subjects received either L-carnitine (2 g/day) plus simvastatin (20 mg/day) or placebo plus simvastatin (20 mg/day) for 12 weeks.
• Lipoprotein (a) [Lp(a)], LDL-C, triacylglycerol (TAG), and apolipoprotein (apo) B levels were measured.

Main Results:

• Lp(a) levels significantly decreased by 19.4% in the L-carnitine/simvastatin group (p=0.01).
• The placebo/simvastatin group showed a non-significant 6.7% reduction in Lp(a) (p=NS vs baseline).
• Both groups experienced similar significant reductions in total cholesterol, LDL-C, apo B, and TAG.

Conclusions:

• Co-administration of L-carnitine with simvastatin provides a significant, modest reduction in Lp(a) compared to simvastatin alone.
• This combination therapy may be a valuable strategy for managing mixed hyperlipidemia with elevated Lp(a).
• Further research is warranted to explore the long-term cardiovascular benefits.